Want to see HK:6978 full AI Analyst Report?
6978 Stock Chart & Stats
HK$2.68
-HK$0.01(-0.43%)
At close: 4:00 PM EST
HK$2.68
-HK$0.01(-0.43%)
Day’s Range― - ―
52-Week RangeHK$0.33 - HK$5.40
Previous CloseN/A
Volume50.00K
Average Volume (3M)1.34M
Market Cap
HK$231.56M
Enterprise ValueHK$369.85
Total Cash (Recent Filing)HK$154.63M
Total Debt (Recent Filing)HK$440.26M
Price to Earnings (P/E)―
Beta0.60
Next Earnings
Mar 19, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.42
Shares Outstanding617,500,800
10 Day Avg. Volume1,608,107
30 Day Avg. Volume1,338,788
Financial Highlights & Ratios
PEG Ratio-0.38
Price to Book (P/B)-103.70
Price to Sales (P/S)0.00
P/FCF Ratio-12.91
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Sizeable Asset BaseA 603.2M asset base provides tangible resources and optionality for a pre-commercial biotech: it can underpin R&D operations, serve as collateral for financing, and lengthen the development runway versus a balance sheet with minimal assets.
Sharp Reduction In DebtA material reduction in debt from 784M to 103.7M cuts interest and covenant pressure, improving solvency metrics and lowering near-term refinancing needs. This structural deleveraging reduces bankruptcy risk and eases funding runway requirements.
Improving Cash Burn And LossesSequential improvement in operating cash flow and narrower net losses indicate management is containing costs and extending runway. These trends, if sustained, lower the pace of external funding required and increase the probability of reaching value-inflection R&D milestones.
Bears Say
No Revenue GenerationZero revenue over multiple years signifies a pre-commercial business model reliant entirely on financing and R&D progress. Without product sales, the company lacks internally generated cash flow, amplifying execution and funding risk over the medium term.
Negative Stockholders' EquityNegative equity is a structural solvency concern that limits access to traditional financing, increases creditor risk aversion, and can trigger covenant issues or restructurings. It materially elevates long-run funding and insolvency risk for the business.
Persistent Cash BurnConsistent negative operating and free cash flow means the company is not self-funding and remains dependent on external capital. Continued cash burn creates dilution and execution risk if capital markets tighten or if development milestones slip.
Immunotech Biopharm Ltd News
6978 FAQ
What was Immunotech Biopharm Ltd’s price range in the past 12 months?
Immunotech Biopharm Ltd lowest stock price was HK$0.33 and its highest was HK$5.40 in the past 12 months.
What is Immunotech Biopharm Ltd’s market cap?
Immunotech Biopharm Ltd’s market cap is HK$231.56M.
When is Immunotech Biopharm Ltd’s upcoming earnings report date?
Immunotech Biopharm Ltd’s upcoming earnings report date is Mar 19, 2027 which is in 203 days.
How were Immunotech Biopharm Ltd’s earnings last quarter?
Immunotech Biopharm Ltd released its earnings results on Aug 21, 2026. The company reported -HK$0.129 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Immunotech Biopharm Ltd overvalued?
According to Wall Street analysts Immunotech Biopharm Ltd’s price is currently Overvalued.
Does Immunotech Biopharm Ltd pay dividends?
Immunotech Biopharm Ltd does not currently pay dividends.
What is Immunotech Biopharm Ltd’s EPS estimate?
Immunotech Biopharm Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Immunotech Biopharm Ltd have?
Immunotech Biopharm Ltd has 617,500,800 shares outstanding.
What happened to Immunotech Biopharm Ltd’s price movement after its last earnings report?
Immunotech Biopharm Ltd reported an EPS of -HK$0.129 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 1.299%.
Which hedge fund is a major shareholder of Immunotech Biopharm Ltd?
Currently, no hedge funds are holding shares in HK:6978
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Immunotech Biopharm Ltd Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
62.94%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
11.88%
Trailing 12-Months
Company Description
Immunotech Biopharm Ltd
Immunotech Biopharm Ltd operates as a biopharmaceutical firm specializing in cellular immunotherapy. Its primary activities involve the investigation, development, and market introduction of T cell-based immunotherapy solutions for various cancers within the People's Republic of China. The company's flagship product, EAL, is a multi-target cellular immunotherapy currently undergoing Phase II clinical trials for the purpose of preventing liver cancer recurrence after surgery. Furthermore, Immunotech Biopharm is conducting both preclinical and clinical research on EAL for its potential use in treating lung cancer, glioma, gastric cancer, and colorectal cancer. Other pipeline assets include the 6B11-OCIK injection, which is in Phase I trials for ovarian cancer; the CAR-T-19 injection product, targeting B-cell acute lymphoblastic leukaemia; and a range of TCR-T cell products designed for solid tumor treatment. Established in 2006, the company's main office is located in Beijing, China.
Technical Analysis
Brii Biosciences Limited
―
JW (Cayman) Therapeutics Co. Ltd.
―
Mabpharm Limited
―
Transcenta Holding Limited
―
Wuhan YZY Biopharma Co., Ltd. Class H
―